Advances in the Management of Parkinson’s Disease–Related Psychosis in Long-Term Care (CME/CE Webcast)
Activity Description and Purpose
In this webcast, practicing experts in geriatrics and geriatric psychiatry (Dr Malcolm Fraser and Dr George Grossberg) provide a practical long-term care–centric approach to the diagnosis and management of hallucinations and delusions in residents with Parkinson’s disease. Guidelines, new treatments, and implications for state surveys are discussed. A case illustrates health care team communications for optimal resident/care provider interactions.
This educational activity is intended for medical directors, attending physicians, nurse practitioners, and physician assistants caring for patients with Parkinson’s disease in the long-term care setting.
After completing this activity, participants will be better able to:
- Identify the signs and symptoms of Parkinson’s disease psychosis
- Design effective communication strategies for assessing symptoms of psychosis in patients with Parkinson’s disease
- Adapt management plans for patients with psychotic symptoms according to the latest guidance on appropriate use of antipsychotics
- Develop individualized management plans for long-term care residents who experience psychosis
Malcolm Fraser, MD, CMD (Chair)
George T. Grossberg, MD
Samuel W. Fordyce Professor
Director, Geriatric Psychiatry
Department of Psychiatry and Behavioral Neuroscience
Saint Louis University School of Medicine
St Louis, Missouri
MedEdicus LLC adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to accreditation of the activity.
Malcom Fraser, MD, is a consultant for ACADIA Pharmaceuticals Inc, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, and Sun Pharmaceutical Industries, Inc; and is on speakers bureau for ACADIA Pharmaceuticals Inc, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc.
George T. Grossberg, MD, is a consultant for ACADIA Pharmaceuticals Inc, Alkahest, Inc, Avanir Pharmaceuticals, Inc, Axsome Therapeutics, Inc, Biogen Idec, BioXcel Therapeutics, F. Hoffmann-La Roche Ltd, Genentech, Inc, H. Lundbeck A/S, Karuna Therapeutics, Otsuka America Pharmaceutical, Inc, and Takeda Pharmaceuticals USA, Inc; is on the speakers bureau for ACADIA Pharmaceuticals Inc and Biogen Idec; is a contracted researcher for Eli Lilly and Company, Janssen Global Services, LLC, and Nia Therapeutics; and receives other funding (Safety Monitoring Committee) from Avanex Corporation, EryDel SPA, Merck & Co., Inc, and Newron Pharmaceuticals SPA.
Peer Reviewer Disclosure
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or ACADIA Pharmaceuticals Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2022. All rights reserved. 262.1
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation